Ausgabe 9/2008
Inhalt (15 Artikel)
Anti-tumor activity and trafficking of self, tumor-specific T cells against tumors located in the brain
- Original Article
Robert M. Prins, Chengyi J. Shu, Caius G. Radu, Dan D. Vo, Haumith Khan-Farooqi, Horacio Soto, Meng-Yin Yang, Muh-Shi Lin, Stephanie Shelly, Owen N. Witte, Antoni Ribas, Linda M. Liau
Tumor destruction using electrochemotherapy followed by CpG oligodeoxynucleotide injection induces distant tumor responses
- Original Article
Stephan Roux, Claire Bernat, Bassim Al-Sakere, François Ghiringhelli, Paule Opolon, Antoine F. Carpentier, Laurence Zitvogel, Lluis M. Mir, Caroline Robert
Development of a Listeria monocytogenes based vaccine against prostate cancer
- Original Article
Vafa Shahabi, Mariela Reyes-Reyes, Anu Wallecha, Sandra Rivera, Yvonne Paterson, Paulo Maciag
Impact of IFNα2b upon pSTAT3 and the MEK/ERK MAPK Pathway in Melanoma
- Original Article
Wenjun Wang, Howard D. Edington, Drazen M. Jukic, Uma N. M. Rao, Stephanie R. Land, John M. Kirkwood
Experimental manipulations of afferent immune responses influence efferent immune responses to brain tumors
- Original Article
Diana L. Thomas, David M. Kranz, Edward J. Roy
High frequency of immature dendritic cells and altered in situ production of interleukin-4 and tumor necrosis factor-α in lung cancer
- Original Article
R. B. Baleeiro, L. B. Anselmo, F. A. Soares, C. A. L. Pinto, O. Ramos, J. L. Gross, F. Haddad, R. N. Younes, M. Y. Tomiyoshi, P. C. Bergami-Santos, J. A. M. Barbuto
Investigation of the mechanisms of tissue factor-mediated evasion of tumour cells from cellular cytotoxicity
- Original Article
Chao Li, Mary E. W. Collier, G. Alkisitis Frentzou, John Greenman, Camille Ettelaie
Fas-mediated T cell deletion potentiates tumor antigen-specific tolerance in a mouse model of prostate cancer
- Original Article
Stephanie S. Tseng-Rogenski, Mohamed S. Arredouani, Yilin C. Neeley, Bin Lu, Arul M. Chinnaiyan, Martin G. Sanda
The role of extracellular matrix metalloproteinase inducer protein in prostate cancer progression
- Original Article
Michele C. Madigan, Elizabeth A. Kingsley, Paul J. Cozzi, Warick J. Delprado, Pamela J. Russell, Yong Li
CD54 is a surrogate marker of antigen presenting cell activation
- Original Article
N. A. Sheikh, L. A. Jones
Danger signals and nonself entity of tumor antigen are both required for eliciting effective immune responses against HER-2/neu positive mammary carcinoma: implications for vaccine design
- Original Article
Maciej Kmieciak, Johanna K. Morales, Joshua Morales, Elizabeth Bolesta, Margaret Grimes, Masoud H. Manjili
TARC and RANTES enhance antitumor immunity induced by the GM-CSF-transduced tumor vaccine in a mouse tumor model
- Original Article
Hiroyuki Inoue, Mutsunori Iga, Meng Xin, Saori Asahi, Takafumi Nakamura, Ryo Kurita, Masaharu Nakayama, Yukoh Nakazaki, Koichi Takayama, Yoichi Nakanishi, Kenzaburo Tani
Pilot study of mutant ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers
- Original Article
Antoun Toubaji, Moujahed Achtar, Maurizio Provenzano, Vincent E. Herrin, Robert Behrens, Michael Hamilton, Sarah Bernstein, David Venzon, Barry Gause, Francesco Marincola, Samir N. Khleif
Second international conference on cancer vaccines/adjuvants/delivery for the next decade (CVADD): Heidelberg, Germany, 10–12 October 2007
- Meeting Report
V. Schirrmacher, P. Beckhove, P. Fournier, V. Umansky
